Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 771

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future

Open access
Sedger, Lisa M., McDermott, Michael F.·2014·Cytokine & Growth Factor Reviews
DOI 10.1016/j.cytogfr.2014.07.016
Open this paper in CoChat — free account

Abstract

Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent mediator of inflammation, as well as many normal physiological functions in homeostasis and health, and anti-microbial immunity. It also appears to have a central role in neurobiology, although this area of TNF biology is only recently emerging. Here, we review the basic biology of TNF and its normal effector functions, and discuss the advantages and disadvantages of therapeutic neutralization of TNF - now a commonplace practice in the treatment of a wide range of human inflammatory diseases. With over ten years of experience, and an emerging range of anti-TNF biologics now available, we also review their modes of action, which appear to be far more complex than had originally been anticipated. Finally, we highlight the current challenges for therapeutic intervention of TNF: (i) to discover and produce orally delivered small molecule TNF-inhibitors, (ii) to specifically target selected TNF producing cells or individual (diseased) tissue targets, and (iii) to pre-identify anti-TNF treatment responders. Although the future looks bright, the therapeutic modulation of TNF now moves into the era of personalized medicine with society's challenging expectations of durable treatment success and of achieving long-term disease remission.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cytogfr.2014.07.016

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 342

  1. Green, 1982, Murine tumor necrosis-inducing factor: purification and effects on myelomonocytic leukemia cells, J Natl Cancer Inst, 68, 997
  2. Matthews, 1980, Tumour-necrosis factor from the rabbit. IV. Purification and chemical characterization, Br J Cancer, 42, 416, 10.1038/bjc.1980.253 · doi:10.1038/bjc.1980.253
  3. Ruff, 1980, Purification and physico-chemical characterization of rabbit tumor necrosis factor, J Immunol, 125, 1671, 10.4049/jimmunol.125.4.1671 · DOI · Paper page
  4. Matthews, 1979, Tumour-necrosis factor from the rabbit. III. Relationship to interferons, Br J Cancer, 40, 534, 10.1038/bjc.1979.218 · doi:10.1038/bjc.1979.218
  5. Prince, 1982, Inhibition of L-cell growth in agarose (ILGA): a simple inexpensive method for the detection and quantitation of factors inhibiting tumor cell growth, J Immunol Methods, 48, 367, 10.1016/0022-1759(82)90337-4 · doi:10.1016/0022-1759(82)90337-4
  6. Bloksma, 1983, Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo, Cancer Immunol Immunother, 16, 35, 10.1007/BF00199903 · doi:10.1007/bf00199903
  7. Williamson, 1983, Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon, Proc Natl Acad Sci U S A, 80, 5397, 10.1073/pnas.80.17.5397 · DOI · Paper page
  8. English, 1991, Differential regulation of lymphotoxin and tumor necrosis factor genes in human T lymphocytes, J Biol Chem, 266, 7108, 10.1016/S0021-9258(20)89617-3 · doi:10.1016/s0021-9258(20)89617-3
  9. Kelker, 1985, Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin, Int J Cancer, 36, 69, 10.1002/ijc.2910360112 · DOI
  10. Turner, 1988, Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 mRNA, Biochem Biophys Res Commun, 153, 1144, 10.1016/S0006-291X(88)81347-0 · doi:10.1016/s0006-291x(88)81347-0
  11. Fransen, 1985, Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression, Nucleic Acids Res, 13, 4417, 10.1093/nar/13.12.4417 · DOI · Paper page
  12. Shirai, 1985, Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor, Nature, 313, 803, 10.1038/313803a0 · DOI · Paper page
  13. Wang, 1985, Molecular cloning of the complementary DNA for human tumor necrosis factor, Science, 228, 149, 10.1126/science.3856324 · DOI · Paper page
  14. Haranaka, 1984, Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice, Int J Cancer, 34, 263, 10.1002/ijc.2910340219 · DOI · Paper page
  15. Ziegler-Heitbrock, 1986, Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity, Cancer Res, 46, 5947
  16. Haranaka, 1987, Antitumour effects of tumour necrosis factor: cytotoxic or necrotizing activity and its mechanism, Ciba Found Symp, 131, 140
  17. Creaven, 1987, Phase I clinical trial of recombinant human tumor necrosis factor, Cancer Chemother Pharmacol, 20, 137, 10.1007/BF00253968 · DOI
  18. Feinberg, 1988, A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients, J Clin Oncol, 6, 1328, 10.1200/JCO.1988.6.8.1328 · DOI · Paper page
  19. Schwartz, 1989, A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy, Biotherapy, 1, 207, 10.1007/BF02170889 · doi:10.1007/bf02170889
  20. Zamkoff, 1989, A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy, J Biol Response Mod, 8, 539
  21. Negrier, 1991, Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer, J Immunother, 11, 93, 10.1097/00002371-199202000-00003 · doi:10.1097/00002371-199202000-00003
  22. Roberts, 2011, Systemic use of tumor necrosis factor-α as an anticancer agent, Oncotarget, 2, 739, 10.18632/oncotarget.344 · DOI
  23. Beutler, 1985, Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin, Science, 4716
  24. Shalaby, 1989, Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo, Clin Immunol Immunopathol, 53, 488, 10.1016/0090-1229(89)90010-X · DOI · Paper page
  25. Zhang, 1988, Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6, Proc Natl Acad Sci U S A, 85, 6802, 10.1073/pnas.85.18.6802 · DOI · Paper page
  26. Falvo, 2010, Transcriptional control of the TNF gene, Curr Dir Autoimmun, 11, 27, 10.1159/000289196 · DOI · Paper page
  27. Tsai, 1996, Cell-type-specific regulation of the human tumor necrosis factor-α gene in B cells and T cells by NFATp and ATF-2/JUN, Mol Cell Biol, 16, 5232, 10.1128/MCB.16.10.5232 · DOI · Paper page
  28. Tuohy, 1998, The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis, Immunol Rev, 164, 93, 10.1111/j.1600-065X.1998.tb01211.x · DOI
  29. Stamou, 2010, Posttranscriptional regulation of TNF mRNA: a paradigm of signal-dependent mRNA utilization and its relevance to pathology, Curr Dir Autoimmun, 11, 61, 10.1159/000289197 · DOI
  30. Zhang, 2002, AU-rich element-mediated translational control: complexity and multiple activities of trans-activating factors, Biochem Soc Trans, 30, 952, 10.1042/bst0300952 · DOI · Paper page
  31. Moss, 1997, Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha, Nature, 385, 733, 10.1038/385733a0 · DOI · Paper page
  32. Tartaglia, 1991, The two different receptors for tumor necrosis factor mediate distinct cellular responses, Proc Natl Acad Sci U S A, 88, 9292, 10.1073/pnas.88.20.9292 · DOI · Paper page
  33. Grell, 1995, The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor, Cell, 83, 793, 10.1016/0092-8674(95)90192-2 · DOI · Paper page
  34. Carpentier, 2004, Function and regulation of tumor necrosis factor type 2, Curr Med Chem, 11, 2205, 10.2174/0929867043364694 · DOI
  35. Aggarwal, 1985, Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon, Nature, 318, 665, 10.1038/318665a0 · DOI · Paper page
  36. Tsujimoto, 1986, Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor, J Immunol, 136, 2441, 10.4049/jimmunol.136.7.2441 · DOI · Paper page
  37. Tartaglia, 1993, Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor, J Biol Chem, 268, 18542, 10.1016/S0021-9258(17)46661-0 · DOI · Paper page
  38. Eissner, 2004, Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system, Cytokine Growth Factor Rev, 15, 353, 10.1016/j.cytogfr.2004.03.011 · DOI · Paper page
  39. Watts, 1999, A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in ‘reverse signalling’, EMBO J, 18, 2119, 10.1093/emboj/18.8.2119 · DOI · Paper page
  40. Xin, 2006, Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNFα-mediated ‘reverse signaling’, Int J Mol Med, 18, 885
  41. Zhang, 2008, Transmembrane TNF-alpha mediates “forward” and “reverse” signaling, inducing cell death or survival via the NF-κB pathway in Raji Burkitt lymphoma cells, J Leukoc Biol, 84, 789, 10.1189/jlb.0208078 · DOI
  42. Higuchi, 1997, Membrane tumor necrosis factor-alpha (TNF-alpha) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation-characterization of membrane TNF-α, Clin Immunol Immunopathol, 82, 133, 10.1006/clin.1996.4291 · DOI
  43. Parry, 1997, Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha, J Immunol, 158, 3673, 10.4049/jimmunol.158.8.3673 · DOI · Paper page
  44. Xin, 2006, Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated ‘reverse signaling’, Int J Mol Med, 18, 885
  45. Eissner, 2000, Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages, J Immunol, 164, 6193, 10.4049/jimmunol.164.12.6193 · DOI
  46. Hayder, 1999, Adenovirus-induced liver pathology is mediated through TNF receptors I and II but is independent of TNF or lymphotoxin, J Immunol, 163, 1516, 10.4049/jimmunol.163.3.1516 · DOI
  47. Ruddle, 2014, Lymphotoxin and TNF: how it all began-A tribute to the travelers, Cytokine Growth Factor Rev, 25, 83, 10.1016/j.cytogfr.2014.02.001 · DOI
  48. Chan, 2000, A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling, Science, 288, 2351, 10.1126/science.288.5475.2351 · DOI · Paper page
  49. Tartaglia, 1993, Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor, Cell, 73, 213, 10.1016/0092-8674(93)90222-C · DOI · Paper page
  50. Jiang, 1999, Prevention of constitutive TNF receptor 1 signaling by silencer of death domains, Science, 283, 543, 10.1126/science.283.5401.543 · DOI · Paper page
  51. Takada, 2003, Role of SODD in regulation of tumor necrosis factor responses, Mol Cell Biol, 23, 4026, 10.1128/MCB.23.11.4026-4033.2003 · DOI
  52. Hsu, 1996, TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways, Cell, 84, 299, 10.1016/S0092-8674(00)80984-8 · DOI · Paper page
  53. Hsu, 1995, The TNF receptor-1 associated protein TRADD signals cell death and NF-κB activation, Cell, 81, 495, 10.1016/0092-8674(95)90070-5 · DOI · Paper page
  54. Rothe, 1995, TRAF2 mediated activation of NF-κB by TNF receptor-2 and CD40, Science, 269, 1424, 10.1126/science.7544915 · DOI · Paper page
  55. Rothe, 1994, A novel family of putative signal transducers associated with the cytoplasmic domain of the 75kDa tumour necrosis factor receptor, Cell, 78, 681, 10.1016/0092-8674(94)90532-0 · DOI · Paper page
  56. Boldin, 1996, Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death, Cell, 85, 803, 10.1016/S0092-8674(00)81265-9 · DOI · Paper page
  57. Ho, 2005, Mammalian initiator apoptotic caspases, FEBS J, 272, 5436, 10.1111/j.1742-4658.2005.04966.x · DOI · Paper page
  58. Enari, 1998, A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD, Nature, 391, 43, 10.1038/34112 · DOI · Paper page
  59. Muzio, 1996, Flice, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signalling complex, Cell, 85, 817, 10.1016/S0092-8674(00)81266-0 · DOI · Paper page
  60. Vince, 2009, TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (TNF) to efficiently activate NF-κB and to prevent TNF-induced apoptosis, J Biol Chem, 284, 35906, 10.1074/jbc.M109.072256 · DOI
  61. Wang, 1998, NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation, Science, 281, 1680, 10.1126/science.281.5383.1680 · DOI · Paper page
  62. Darzynkiewicz, 1984, Cell cycle-specific effects of tumor necrosis factor, Cancer Res, 44, 83
  63. Austgulen, 1986, Role of monocyte cytotoxic factor in cytolysis of actinomycin D-treated WEHI 164 cells mediated by freshly isolated human adherent mononuclear blood cells, Cancer Res, 46, 4566
  64. Munker, 1987, In vitro action of tumor necrosis factor on myeloid leukemia cells, Blood, 69, 1102, 10.1182/blood.V69.4.1102.1102 · doi:10.1182/blood.v69.4.1102.1102
  65. Suyama, 1985, Effects of murine tumor necrosis factor on friend erythroleukemic cells, Exp Cell Biol, 53, 85
  66. Sedger, 1999, IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression, J Immunol, 163, 920, 10.4049/jimmunol.163.2.920 · DOI · Paper page
  67. Wong, 1992, Antiviral activity of tumour necrosis factor is signaled through the 55-kDa type I TNF receptor, J Immunol, 149, 3350, 10.4049/jimmunol.149.10.3350 · DOI
  68. Mak, 2002, Signaling for survival and apoptosis in the immune system, Arthritis Res, 4, S243, 10.1186/ar569 · DOI
  69. Natoli, 1997, Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway, Science, 275, 200, 10.1126/science.275.5297.200 · DOI · Paper page
  70. Song, 1997, Tumor necrosis factor (TNF)- mediated kinase cascades: bifurcation of nuclear factor-κB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2, Proc Natl Acad Sci U S A, 94, 9792, 10.1073/pnas.94.18.9792 · DOI · Paper page
  71. Shikama, 2004, Caspase-8 and caspase-10 activate NF-κB through RIP, NIK and IKKα kinases, Eur J Immunol, 33, 1998, 10.1002/eji.200324013 · DOI
  72. Zuckerman, 1991, Transcriptional and post-transcriptional mechanisms involved in the differential expression of LPS-induced IL-1 and TNF mRNA, Immunology, 73, 460
  73. Gupta, 1995, Transcription factor ATF2 regulation by the JNK signal transduction pathway, Science, 267, 389, 10.1126/science.7824938 · DOI · Paper page
  74. Westwick, 1994, Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase, J Biol Chem, 269, 26396, 10.1016/S0021-9258(18)47207-9 · DOI · Paper page
  75. Kohase, 1986, Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation, Cell, 45, 659, 10.1016/0092-8674(86)90780-4 · DOI · Paper page
  76. Fransen, 1986, Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines, Eur J Cancer Clin Oncol, 22, 419, 10.1016/0277-5379(86)90107-0 · DOI · Paper page
  77. Zarnegar, 2008, Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK, Nat Immunol, 9, 1371, 10.1038/ni.1676 · DOI · Paper page
  78. Liao, 2004, Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation, J Biol Chem, 279, 26243, 10.1074/jbc.M403286200 · DOI · Paper page
  79. Qing, 2005, Stabilization of basally translated NF-κB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-κB2 p100, J Biol Chem, 280, 40578, 10.1074/jbc.M508776200 · DOI
  80. Razani, 2010, Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKα-mediated phosphorylation, Sci Signal, 3, ra41, 10.1126/scisignal.2000778 · DOI
  81. McPherson, 2012, Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells, J Biol Chem, 287, 23010, 10.1074/jbc.M112.350538 · DOI
  82. Michel, 2014, Activation-induced tumor necrosis factor receptor-associated factor 3 (Traf3) alternative splicing controls the noncanonical nuclear factor κB pathway and chemokine expression in human T cells, J Biol Chem, 289, 13651, 10.1074/jbc.M113.526269 · DOI
  83. Xie, 2011, TNF receptor-associated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling, J Immunol, 186, 143, 10.4049/jimmunol.1000290 · DOI
  84. Haas, 1999, Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction, Mol Cell, 36, 831, 10.1016/j.molcel.2009.10.013 · DOI · Paper page
  85. Tokunaga, 2009, Involvement of linear polyubiquitylation of NEMO in NF-κB activation, Nat Cell Biol, 11, 123, 10.1038/ncb1821 · DOI · Paper page
  86. Chaudhary, 2000, Activation of the NF-κB pathway by caspase 8 and its homologs, Oncogene, 19, 4451, 10.1038/sj.onc.1203812 · DOI · Paper page
  87. Kataoka, 2004, N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-κB signaling pathway, Mol Cell Biol, 24, 2627, 10.1128/MCB.24.7.2627-2636.2004 · DOI · Paper page
  88. Matsuda, 2014, J Biol Chem, 289, 3876, 10.1074/jbc.M113.506485 · DOI
  89. Deng, 2003, A JNK-dependent pathway is required for TNFα-induced apoptosis, Cell, 115, 61, 10.1016/S0092-8674(03)00757-8 · DOI · Paper page
  90. Schwabe, 2004, Differential requirement for c-Jun NH2-terminal kinase in TNFα-Fas-mediated apoptosis in hepatocytes, FASEB J, 18, 720, 10.1096/fj.03-0771fje · DOI
  91. Ruby, 1997, Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors, J Exp Med, 186, 1591, 10.1084/jem.186.9.1591 · DOI
  92. Sedger, 2005, Viral inhibition of tumour necrosis factor-α and TNFα and TNF-receptor induced apoptosis and inflammation, Curr Med Chem Anti Inflam Anti Aller, 4, 597, 10.2174/156801405774933124 · doi:10.2174/156801405774933124
  93. Hiscott, 2006, Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses, Oncogene, 25, 6844, 10.1038/sj.onc.1209941 · DOI
  94. Mohamed, 2009, NFκB inhibitors: strategies from poxviruses, Cell Cycle, 8, 3125, 10.4161/cc.8.19.9683 · DOI
  95. Komiyama, 1994, Inhibition of interleukin-1 beta converting enzyme by the cowpox virus serpin CrmA. An example of cross-class inhibition, J Biol Chem, 269, 19331, 10.1016/S0021-9258(17)32171-3 · DOI · Paper page
  96. Tewari, 1995, Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product, J Biol Chem, 270, 3255, 10.1074/jbc.270.7.3255 · DOI · Paper page
  97. Thome, 1997, Viral FLICE-inhibitory proteins (FLIPS) prevent apoptosis induced by death receptors, Nature, 386, 517, 10.1038/386517a0 · DOI · Paper page
  98. Chan, 2003, A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses, J Biol Chem, 278, 51613, 10.1074/jbc.M305633200 · DOI · Paper page
  99. Warzocha, 1995, Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system, Eur Cytokine Netw, 6, 83
  100. Schütze, 1994, The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction, J Leukoc Biol, 56, 533, 10.1002/jlb.56.5.533 · DOI
  101. Schütze, 1992, TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced “acidic” sphingomyelin breakdown, Cell, 71, 765, 10.1016/0092-8674(92)90553-O · DOI · Paper page
  102. Fiers, 1987, Structure-function relationship of tumour necrosis factor and its mechanism of action, Ciba Found Symp, 131, 109
  103. Adam-Klages, 1996, FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase, Cell, 86, 937, 10.1016/S0092-8674(00)80169-5 · DOI · Paper page
  104. Heinrich, 2004, Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation, Cell Death Differ, 11, 550, 10.1038/sj.cdd.4401382 · DOI · Paper page
  105. Heinrich, 2000, Ceramide as an activator lipid of cathepsin D, Adv Exp Med Biol, 477, 305, 10.1007/0-306-46826-3_33 · DOI
  106. Peppelenbosch, 1991, Multiple signal transduction pathways regulate TNF-induced actin reorganization in macrophages: inhibition of Cdc42-mediated filopodium formation by TNF, J Immunol, 162, 837, 10.4049/jimmunol.162.2.837 · DOI
  107. Boecke, 2012, Factor associated with neutral sphingomyelinase activity mediates navigational capacity of leukocytes responding to wounds and infection: live imaging studies in zebrafish larvae, J Immunol, 189, 1559, 10.4049/jimmunol.1102207 · doi:10.4049/jimmunol.1102207
  108. Nixon, 2009, Sphingolipids in inflammation: pathological implications and potential therapeutic targets, Br J Pharmacol, 158, 982, 10.1111/j.1476-5381.2009.00281.x · DOI · Paper page
  109. Takeda, 1987, Identity of differentiation inducing factor and tumour necrosis factor, Nature, 323, 338, 10.1038/323338a0 · DOI · Paper page
  110. Trinchieri, 1986, Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon, J Exp Med, 164, 1206, 10.1084/jem.164.4.1206 · DOI · Paper page
  111. Jelinek, 1987, Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-α and interleukin 1, J Immunol, 139, 2970, 10.4049/jimmunol.139.9.2970 · DOI · Paper page
  112. Kehrl, 1987, Effect of tumor necrosis factor-α on mitogen-activated human B cells, J Exp Med, 166, 786, 10.1084/jem.166.3.786 · DOI · Paper page
  113. Palombella, 1988, Mitogenic action of tumor necrosis factor in human fibroblasts: interaction with epidermal growth factor and platelet-derived growth factor, J Cell Physiol, 135, 23, 10.1002/jcp.1041350104 · DOI
  114. Vilcek, 1986, Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors, J Exp Med, 163, 632, 10.1084/jem.163.3.632 · DOI · Paper page
  115. Dinarello, 1986, Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1, J Exp Med, 164, 1443
  116. Philip, 1986, Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1, Nature, 323, 86, 10.1038/323086a0 · DOI · Paper page
  117. Brouckaert, 1989, Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon-γ, J Exp Med, 169, 2257, 10.1084/jem.169.6.2257 · DOI
  118. Christoforidis, 2003, Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response, Arch Surg, 138, 17, 10.1001/archsurg.138.1.17 · doi:10.1001/archsurg.138.1.17
  119. Waage, 1989, The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome, J Exp Med, 169, 333, 10.1084/jem.169.1.333 · DOI · Paper page
  120. Waage, 1989, Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis, relation to the inflammatory response, J Exp Med, 170, 1859, 10.1084/jem.170.6.1859 · DOI · Paper page
  121. Dinarello, 1991, The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome, J Infect Dis, 163, 1177, 10.1093/infdis/163.6.1177 · DOI · Paper page
  122. McDermott, 1999, Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes, Cell, 97, 133, 10.1016/S0092-8674(00)80721-7 · DOI · Paper page
  123. Rebelo, 2006, Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function, Arthritis Rheum, 54, 2674, 10.1002/art.21964 · DOI
  124. Todd, 2004, Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour, Immunology, 113, 65, 10.1111/j.1365-2567.2004.01942.x · DOI
  125. Yousaf, 2005, Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-κB activation, Arthritis Rheum, 52, 2906, 10.1002/art.21268 · doi:10.1002/art.21268
  126. Lobito, 2006, Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS), Blood, 108, 1320, 10.1182/blood-2005-11-006783 · DOI · Paper page
  127. Dickie, 2012, Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome, Ann Rheum Dis, 71, 2035, 10.1136/annrheumdis-2011-201197 · DOI
  128. Kimberley, 2007, Falling into TRAPS – receptor misfolding in the TNF receptor 1-associated periodic fever syndrome, Arthritis Res Ther, 9, 217, 10.1186/ar2197 · DOI
  129. Savic, 2012, Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives, Best Pract Res Clin Rheumatol, 26, 505, 10.1016/j.berh.2012.07.009 · DOI
  130. Bulua, 2012, Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study, Arthritis Rheum, 64, 908, 10.1002/art.33416 · DOI
  131. Vaitla, 2011, Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab, Arthritis Rheum, 63, 1151, 10.1002/art.30215 · DOI
  132. Cantarini, 2012, Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives, Autoimmun Rev, 12, 38, 10.1016/j.autrev.2012.07.020 · DOI
  133. Wong, 1986, Tumour necrosis factors α and β inhibit virus replication and synergize with interferons, Nature, 323, 819, 10.1038/323819a0 · DOI · Paper page
  134. Yamaguchi, 1997, Contrasting effects of TGFβ1 and TNFα on the development of dendritic cells from progenitors in mouse bone marrow, Stem Cells, 15, 144, 10.1002/stem.150144 · DOI · Paper page
  135. Takashiba, 1999, Differentiation of monocytes to macrophages primes cells for lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear factor κB, Infect Immun, 67, 5573, 10.1128/IAI.67.11.5573-5578.1999 · DOI · Paper page
  136. Harris, 2008, Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis, J Infect Dis, 198, 1842, 10.1086/593174 · DOI
  137. Zhou, 2014, Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways, Cell Signal, 26, 192, 10.1016/j.cellsig.2013.11.004 · DOI · Paper page
  138. Cohen, 2013, Extrinsic and intrinsic control of macrophage inflammatory responses, J Leukoc Biol, 94, 913, 10.1189/jlb.0413236 · DOI
  139. Aversa, 1997, The 26-kD transmembrane form of tumor necrosis factor-α on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation, J Exp Med, 177, 1575, 10.1084/jem.177.6.1575 · DOI
  140. Upton, 1991, Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence, Virology, 184, 370, 10.1016/0042-6822(91)90853-4 · doi:10.1016/0042-6822(91)90853-4
  141. Schreiber, 1994, The myxoma virus TNF-receptor homologue (T2) inhibits tumor necrosis factor-α in a species-specific fashion, Virology, 204, 692, 10.1006/viro.1994.1585 · DOI
  142. Schreiber, 1996, Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFα, but the dimer is a more potent TNF inhibitor, J Biol Chem, 271, 13333, 10.1074/jbc.271.23.13333 · DOI
  143. Schreiber, 1997, Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition, J Virol, 71, 2171, 10.1128/JVI.71.3.2171-2181.1997 · DOI
  144. Sedger, 1996, M-T2: a poxvirus TNF receptor homologue with dual activities, Immunol Cell Biol, 74, 538, 10.1038/icb.1996.87 · DOI
  145. Skelly, 2013, A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1B, TNF-α and IL-6 challenges in C57BL/6 mice, PLoS One, 8, e69123, 10.1371/journal.pone.0069123 · DOI · Paper page
  146. Thomson, 2014, Peripheral inflammation is associated with remote global gene expression changes in the brain, J Neuroinflammation, 11, 73, 10.1186/1742-2094-11-73 · DOI
  147. Clark, 2010, The roles of TNF in brain dysfunction and disease, Pharmacol Ther, 128, 519, 10.1016/j.pharmthera.2010.08.007 · DOI · Paper page
  148. McCoy, 2008, TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease, J Neuroinflammation, 5, 45, 10.1186/1742-2094-5-45 · DOI · Paper page
  149. Kogo, 2006, Involvement of TNF-α in glutamate-induced apoptosis in a differentiated neuronal cell line, Brain Res, 1122, 201, 10.1016/j.brainres.2006.09.006 · DOI
  150. Kisiswa, 2013, TNFα reverse signaling promotes sympathetic axon growth and target innervation, Nat Neurosci, 16, 865, 10.1038/nn.3430 · DOI
  151. Siegel, 1995, The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo, Cytokine, 7, 15, 10.1006/cyto.1995.1003 · DOI · Paper page
  152. Scallon, 1995, Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions, Cytokine, 7, 251, 10.1006/cyto.1995.0029 · DOI · Paper page
  153. den Broeder, 2002, Long term anti-tumour necrosis factor-α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation, Ann Rheum Dis, 61, 311, 10.1136/ard.61.4.311 · DOI
  154. Weinblatt, 2003, Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial, Arthritis Rheum, 48, 35, 10.1002/art.10697 · DOI · Paper page
  155. van de Putte, 2004, Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed, Ann Rheum Dis, 63, 508, 10.1136/ard.2003.013052 · DOI · Paper page
  156. Klareskog, 2004, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, Lancet, 363, 675, 10.1016/S0140-6736(04)15640-7 · DOI · Paper page
  157. Lethaby, 2013, Etanercept for the treatment of rheumatoid arthritis, Cochrane Database Syst Rev, 5, CD004525
  158. van der Heijde, 2006, Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial, Arthritis Rheum, 54, 1063, 10.1002/art.21655 · DOI · Paper page
  159. Weinblatt, 1999, A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N Engl J Med, 340, 253, 10.1056/NEJM199901283400401 · DOI · Paper page
  160. Hutas, 2010, Golimumab as the first monthly subcutaneous fully human anti-TNF-α antibody in the treatment of inflammatory arthropathies, Immunotherapy, 2, 453, 10.2217/imt.10.34 · doi:10.2217/imt.10.34
  161. Smolen, 2009, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor-α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial, Lancet, 374, 210, 10.1016/S0140-6736(09)60506-7 · DOI · Paper page
  162. Oldfield, 2009, Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, BioDrugs, 23, 125, 10.2165/00063030-200923020-00005 · DOI
  163. Chapman, 2002, PEGylated antibodies and antibody fragments for improved therapy: a review, Adv Drug Deliv Rev, 54, 531, 10.1016/S0169-409X(02)00026-1 · DOI · Paper page
  164. Bourne, 2008, A PEGylated Fab’ fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action, BioDrugs, 22, 331, 10.2165/00063030-200822050-00005 · DOI
  165. Sandborn, 2007, Certolizumab pegol for the treatment of Crohn's disease, N Engl J Med, 357, 228, 10.1056/NEJMoa067594 · DOI · Paper page
  166. Schreiber, 2007, Maintenance therapy with certolizumab pegol for Crohn's disease, N Engl J Med, 357, 239, 10.1056/NEJMoa062897 · DOI · Paper page
  167. Geiler, 2011, Anti-TNF treatment in rheumatiod athritis, Curr Pharm Des, 17, 3141, 10.2174/138161211798157658 · DOI
  168. Meroni, 2014, Tumour necrosis factor-α antagonists in the treatment of Rheumatoid arthritis: an immunological perspective, BioDrugs, 28, S5, 10.1007/s40259-013-0063-0 · DOI
  169. Edwards, 1999, PEGylated recombinat human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-R1): novel high affinity TNF receptor desgined for chonic inflammatory diseases, Ann Rheum Dis, 58, I73, 10.1136/ard.58.2008.i73 · DOI
  170. Bendele, 1999, Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats, Clin Exp Rheumatol, 17, 553
  171. McComb, 1999, Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy, J Rheumatol, 26, 1347
  172. Trinchard-Lugan, 2001, Safety, pharmakinetics and pharmacodynamics of recombinant human tumour necrosis factor binding proteins-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers, Eur Cytokine Netw, 12, 391
  173. Kay, 2013, Biosimilars to treat inflammatory arthritis: the challenge of proving identity, Ann Rheum Dis, 72, 1589, 10.1136/annrheumdis-2012-203198 · doi:10.1136/annrheumdis-2012-203198
  174. Scheinberg, 2012, The advent of biosimilar therapies in rheumatology-“O brave new world”, Nat Rev Rheumatol, 8, 430, 10.1038/nrrheum.2012.84 · doi:10.1038/nrrheum.2012.84
  175. Yoo, 2013, A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study, Ann Rheum Dis, 72, 1613, 10.1136/annrheumdis-2012-203090 · DOI · Paper page
  176. Park, 2013, A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study, Ann Rheum Dis, 72, 1605, 10.1136/annrheumdis-2012-203091 · DOI · Paper page
  177. Fürst, 2014, Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress, Mediat Inflamm, 2014, 146832, 10.1155/2014/146832 · DOI · Paper page
  178. Sharma, 2007, Pharmacokinetics and pharmacodynamics of curcumin, Adv Exp Med Biol, 595, 453, 10.1007/978-0-387-46401-5_20 · DOI · Paper page
  179. Doggui, 2012, Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line, J Alzheimers Dis, 20, 377, 10.3233/JAD-2012-112141 · DOI
  180. Ray, 2011, Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: implications for Alzheimer's disease, J Alzheimers Dis, 23, 61, 10.3233/JAD-2010-101374 · DOI · Paper page
  181. Monroy, 2013, Curcumin and neurodegenerative diseases, Biofactors, 39, 122, 10.1002/biof.1063 · DOI · Paper page
  182. Somers, 1960, Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug, Br J Pharmacol Chemother, 15, 111, 10.1111/j.1476-5381.1960.tb01217.x · DOI
  183. Leck, 1962, Incidence of malformations since the introduction of thalidomide, Br Med J, 2, 16, 10.1136/bmj.2.5296.16 · doi:10.1136/bmj.2.5296.16
  184. Majumdar, 2002, Thalidomide suppresses NF-κB activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester, J Immunol, 168, 2644, 10.4049/jimmunol.168.6.2644 · DOI · Paper page
  185. Majumder, 2012, TNF α signaling beholds thalidomide saga: a review of mechanistic role of TNF-α signaling under thalidomide, Curr Top Med Chem, 12, 1456, 10.2174/156802612801784443 · DOI
  186. Zhou, 2013, Thalidomide-a notorious sedative to a wonder anticancer drug, Curr Med Chem, 20, 4102, 10.2174/09298673113209990198 · DOI
  187. Tweedie, 2012, Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease, J Neuroinflamm, 9, 106, 10.1186/1742-2094-9-106 · DOI · Paper page
  188. He, 2013, Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease, PLoS One, 8, e55091, 10.1371/journal.pone.0055091 · DOI
  189. Kirchner, 2004, Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes, Cytokine, 28, 67, 10.1016/j.cyto.2004.06.008 · DOI
  190. Mitoma, 2005, Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α, Gastroenterology, 128, 376, 10.1053/j.gastro.2004.11.060 · DOI · Paper page
  191. Ringheanu, 2004, Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease, Inflamm Bowel Dis, 10, 801, 10.1097/00054725-200411000-00015 · doi:10.1097/00054725-200411000-00015
  192. Xin, 2006, Dual regulation of soluble tumour necrosis factor-α inducing activation of human monocytic cells via modulation transmembrane TNFα-metiated “reverse signalling”, Int J Mol Med, 18, 885
  193. Marotte, 2014, Etanercept – TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?, Expert Opin Biol Ther, 14, 569, 10.1517/14712598.2014.896334 · DOI
  194. Rutgeerts, 1999, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, Gastroenterology, 117, 761, 10.1016/S0016-5085(99)70332-X · DOI · Paper page
  195. Sandborn, 2001, Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterology, 121, 5, 10.1053/gast.2001.28674 · DOI · Paper page
  196. Mitoma, 2005, Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α, Gastroenterology, 128, 376, 10.1053/j.gastro.2004.11.060 · DOI · Paper page
  197. Taylor, 2010, Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases, Curr Opin Pharmacol, 10, 308, 10.1016/j.coph.2010.01.005 · DOI
  198. Di Sabatino, 2004, Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease, Gut, 53, 70, 10.1136/gut.53.1.70 · DOI
  199. Van den Brande, 2003, Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease, Gastroenterology, 124, 1774, 10.1016/S0016-5085(03)00382-2 · DOI · Paper page
  200. Vos, 2011, Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner, Gastroenterology, 140, 221, 10.1053/j.gastro.2010.10.008 · DOI

200 of 342 shown

Cited by

See all 771

Metadata

Authors
Sedger, L. M., & McDermott, M. F.
Venue
Cytokine & Growth Factor Reviews
Publisher
Elsevier BV
Published
2014-08
Volume
25
Issue
4
Pages
453-472
ISSN
1359-6101 (ISSN-L)
DOI
10.1016/j.cytogfr.2014.07.016
OpenAlex
W1964249139
Cited by
771
References
15
FWCI
8.75
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future. https://app.cochat.ai/papers/10.1016/j.cytogfr.2014.07.016
The paper
Sedger, L. M., & McDermott, M. F. (2014). TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine & Growth Factor Reviews. https://doi.org/10.1016/j.cytogfr.2014.07.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.